Veterinary Antibody Therapies: R&D Progress, Technical Barriers, and Next-Gen Discovery Strategies (

Veterinary antibody therapy is moving from a specialized research area toward a practical therapeutic modality for companion animals. Monoclonal antibodies offer high target specificity, prolonged biological activity, and the potential to control disease pathways that may be difficult to address with conventional small-molecule drugs. These advantages are particularly relevant to chronic conditions requiring long-term management, including osteoarthritis, allergic dermatitis, inflammatory disorders, infectious diseases, and cancer.

The progress of products targeting interleukin-31 and nerve growth factor has demonstrated that species-adapted antibodies can provide clinically meaningful options for dogs and cats. In the United States, frunevetmab became the first monoclonal antibody approved by the FDA for use in any animal species, followed by bedinvetmab as the first FDA-approved monoclonal antibody for controlling osteoarthritis pain in dogs. A conditionally licensed canine parvovirus monoclonal antibody has also expanded interest in antibody-based intervention for veterinary infectious diseases.

These milestones indicate that veterinary antibody R&D is no longer limited to adapting human biologics. The field is developing its own target-discovery methods, species-specific antibody libraries, functional models, and regulatory strategies. Nevertheless, translating a biological hypothesis into a safe, manufacturable, and commercially realistic veterinary antibody remains technically demanding.

Why Veterinary Antibody Development Requires a Species-Specific Strategy

The apparent similarity between a human disease and its veterinary counterpart does not guarantee that the same antibody will work in both species. Differences in protein sequences, receptor structures, immune signaling, antibody constant regions, tissue distribution, and disease progression can substantially affect therapeutic performance.

An antibody originating from another species may trigger an anti-drug immune response when administered repeatedly. This response can accelerate antibody clearance, reduce efficacy, or produce safety concerns. Consequently, canine antibodies intended for dogs and felinized antibodies intended for cats must be designed to interact appropriately with the recipient’s immune system. The approved feline antibody frunevetmab, for example, retains the antigen-recognizing regions required for target binding while replacing most murine antibody regions with feline counterparts.

Species adaptation alone, however, is not sufficient. A successful veterinary antibody must also demonstrate suitable affinity, specificity, biological function, pharmacokinetics, stability, and manufacturability. Researchers therefore need to consider the complete target-to-candidate workflow rather than treating antibody discovery as an isolated screening experiment.

This begins with target selection. Comparative medicine can provide useful hypotheses, but targets identified in human studies should be confirmed in canine or feline samples. Modern pet therapeutic antibody target discovery increasingly combines genomics, transcriptomics, proteomics, bioinformatics, and functional screening. These methods can reveal disease-associated variants, altered expression patterns, signaling networks, and cell-surface proteins that may be suitable for therapeutic intervention.

Multi-omics analysis is most valuable when supported by experimental validation. Elevated RNA expression does not necessarily mean that an accessible, functional protein is present on the relevant cell type. Candidate targets should therefore be confirmed at the protein and tissue levels, followed by loss-of-function, blocking, pathway, or disease-model studies that demonstrate a causal relationship with the therapeutic outcome.

Key Technical Barriers Across the Discovery Pipeline

One of the most persistent barriers is antigen quality. Antibody screening outcomes depend heavily on how the target is presented. A recombinant protein that is incorrectly folded, improperly glycosylated, or missing a relevant extracellular domain may generate antibodies that bind the screening reagent but fail to recognize the native target.

The choice of expression system must reflect the biological characteristics of the antigen. Bacterial expression may be efficient for simple, nonglycosylated proteins, whereas mammalian or insect-cell expression may be necessary for complex extracellular proteins and receptors. Researchers may also need multiple antigen formats, such as soluble extracellular domains, Fc-fusion proteins, stabilized proteins, peptides, or target-expressing cells.

Access to characterized veterinary antigen products can help researchers compare formats and establish reproducible immunization, panning, binding, and functional assays. Available recombinant and native antigens covering canine, feline, and other veterinary targets can also support vaccine research, diagnostic development, cross-reactivity testing, and antibody characterization.

A second barrier is insufficient antibody diversity. Conventional immunization and hybridoma methods remain useful, but they may not capture rare clones against conserved, weakly immunogenic, membrane-associated, or structurally complex targets. Phage display, single-B-cell technologies, and immune repertoire sequencing can broaden the accessible sequence space and reduce dependence on a single discovery method.

For canine programs, a dedicated canine therapeutic antibody discovery platform can provide libraries derived from canine immune sequences rather than requiring extensive conversion of antibodies discovered in unrelated species. Such platforms may combine large phage-display libraries with target-specific panning, clone sequencing, recombinant expression, affinity assessment, functional testing, and lead optimization.

A third challenge is the gap between binding and therapeutic function. High-affinity binding does not automatically produce receptor blockade, ligand neutralization, pathogen clearance, immune-cell activation, or tumor-cell killing. Screening strategies should therefore include functional assays as early as possible. Cell-based competition assays, signaling measurements, cytokine analysis, internalization studies, neutralization assays, and species-relevant primary cells can help eliminate nonfunctional binders before expensive development work begins.

The availability of broader animal health research products, including antibodies, antigens, cell lines, and primary cells, can facilitate this transition from biochemical binding assays to biologically relevant evaluation.

Integrated Strategies for Breaking Development Barriers

A more effective development strategy connects target biology, antigen engineering, antibody discovery, functional validation, and developability assessment within one iterative workflow.

During target discovery, researchers can combine population-level genomic information with disease-tissue transcriptomics and proteomics. Targets supported by several independent datasets should then be evaluated for accessibility, selectivity, normal-tissue expression, pathway relevance, and potential safety liabilities. This evidence-based filtering reduces the risk of launching a resource-intensive antibody campaign around a weak biological hypothesis.

During antibody discovery, parallel screening methods can increase the probability of identifying functionally distinct candidates. Phage display may offer broad sequence diversity and controlled selection conditions, while immunization-based or single-cell methods can recover naturally matured antibodies. Counterselection against homologous proteins and normal cells can improve specificity, while cross-species screening can identify candidates useful for both therapeutic development and preclinical studies.

Developability testing should also begin earlier. Aggregation, nonspecific binding, poor expression, chemical instability, excessive hydrophobicity, and unfavorable viscosity can undermine an otherwise promising antibody. Early sequence analysis, recombinant expression, thermal-stability testing, serum-stability assessment, and accelerated formulation studies make it possible to identify these liabilities before lead selection.

Specialized veterinary antibody technology platforms can help integrate these activities through canine- and feline-specific discovery systems, molecular engineering, bioinformatics, phage display, characterization, and preclinical support.

Safety evaluation remains equally important. The FDA’s post-approval review of adverse-event reports involving bedinvetmab illustrates why pharmacovigilance must continue after commercialization. Reported events do not by themselves establish causality, but they provide signals that regulators, manufacturers, and veterinarians must evaluate carefully.

The next phase of veterinary antibody R&D will therefore be defined not simply by producing more antibodies, but by producing better-supported candidates. Species-specific target validation, native-like antigens, diverse discovery libraries, predictive functional models, early developability screening, and long-term safety monitoring will be central to progress.

As these capabilities mature, veterinary antibody therapies may expand beyond pain and dermatology into oncology, infectious disease, immune-mediated disorders, and precision treatment for defined animal populations. The most successful programs will be those that combine biological insight with coordinated, species-appropriate development from the beginning.

A fan of biotechnology who likes to post articles in relevant fields regularly